Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items